CLINICAL PEARLS: Evaluating Outcomes of New Technologies

    The issues surrounding metal-on-metal hip implants – patient morbidity, product withdrawals, lawsuits, FDA warnings – have made it very clear that orthopaedic surgeons need to proceed with caution when evaluating new technologies they may want to introduce into their practice.

    A key piece of the evaluation process is reviewing outcomes data. But that can be challenging: In orthopaedics, “mid-term” is generally considered to be 10 years at a minimum, with “long-term” meaning 20 years or more.

    So how can orthopaedic surgeons objectively evaluate outcomes in new technologies? David G. Lewallen, MD, from Mayo Clinic in Rochester, Minnesota, has some thoughts on the issue, which he shared in an exclusive interview with ICJR.

    Click the images below to hear his comments.

    Evaluating new technology

    Applicability of 20- to 30-year outcomes

    Outcomes with newer technology

    Producer: Michael Szuch; Director: Michael Bugera; Post Production: Charles Maynard